BrianAndrewVan TineMD
Oncology • Saint Peters, MOHematologic Oncology, Sarcoma
Instructor, Internal Medicine, Washington University School of Medicine
Dr. Van Tine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
150 Entrance Way
# Dv
Saint Peters, MO 63376Phone+1 800-647-2098Fax+1 314-362-3192
Summary
- I have set out on a lifelong mission to make an impact in the treatment of patients with sarcoma. I spent the first three years of my career developing a very large and robust trials-based sarcoma program at Washington University in St. Louis. This is now the largest program in the Midwest, and I have been the PI of over 40 clinical trials. I was awarded an early career development grant by the Sarcoma Alliance through Research and Collaboration.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
University of Alabama School of MedicineClass of 2005
Certifications & Licensure
OH State Medical License Current
IL State Medical License 2020 - 2026
MO State Medical License 2007 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma Start of enrollment: 2021 Jan 05
- 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111 Start of enrollment: 2021 Dec 31
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 2020 Jan 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsCardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.Robin L. Jones, Thomas J. Herzog, Shreyaskumar Patel, Margaret von Mehren, Scott M. Schuetze
Cancer Medicine. 2021-05-07 - 97 citationsClonal Selection for Transcriptionally Active Viral Oncogenes during Progression to CancerBrian A. Van Tine, John C. Kappes, N. Sanjib Banerjee, Judith F. Knops, Lilin Lai
Journal of Virology. 2004-10-15 - 273 citationsCell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription.Tianlin Ma, Brian A. Van Tine, Yue Wei, Michelle D. Garrett, David M. Nelson
Genes & Development. 2000-09-15
Lectures
- A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 p...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.2019 ASCO Annual Meeting - 6/1/2019
- Emerging Agents: Metabolism, DNA Repair, and Hypoxia2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Committees
- Member, NRG Sarcoma Committee 2014 - Present
Research History
- Sarcoma Alliance for Research2012 - 2015
Professional Memberships
- Sarcoma Working Group of AllianceCo-Chair
- Sarcoma Survivorship working group of SWOGMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
